Orphazyme reports USD 90m deficit for 2021
Danish biotech firm Orphazyme, which has now been sold to Kempharm in the US, has finally released its 2021 financial report, detailing a USD 90m loss on the bottom line.
by marketwire, translated by catherine brett
At the end of 2022, Orphazyme expects to have DKK 30m (USD 4.3m) in the bank, its financial report for 2021 states.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Orphazyme CEO on sale: "It’s sad, but we tried everything"
For subscribers
Orphazyme is now officially in American hands
For subscribers
Orphazyme's fate sealed as creditors approve Kempharm sale
For subscribers
